BA
ARGS

BlackRock Advisors’s Argos Therapeutics, Inc. ARGS Stock Holding History

BlackRock Advisors’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$29K Buy
297
+17
+6% +$1.59K ﹤0.01% 3383
2016
Q3 		$28K Buy
280
+134
+92% +$14K ﹤0.01% 3384
2016
Q2 		$18K Buy
+146
New +$19.5K ﹤0.01% 3475
2014
Q2 		– Sell
-31
Closed -$6K – 3802
2014
Q1 		$6K Buy
+31
New +$6.2K ﹤0.01% 3595

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's ARGS Position: Q4 2016 in Review

BlackRock Advisors increased its Argos Therapeutics, Inc. (ARGS) stake by 6.1% in Q4 2016, buying an estimated $1.59K and bringing the position to 297 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

BlackRock Advisors first reported a position in ARGS in Q1 2014 and has held it in 4 quarters since. 52 funds tracked by Wall St. Rank hold ARGS as of Q4 2016.

  • BlackRock Advisors held 297 shares of Argos Therapeutics, Inc. worth $29K as of Q4 2016.
  • BlackRock Advisors bought 17 Argos Therapeutics, Inc. shares in Q4 2016, an estimated $1.59K.
  • Argos Therapeutics, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3383 holding.
  • BlackRock Advisors first reported a position in Argos Therapeutics, Inc. in Q1 2014 and has held it in 4 quarters since.
  • 52 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.